Phospho-LATS1/LATS2 (T1079/1041) Antibody

What is the biological significance of LATS1/LATS2 T1079/T1041 phosphorylation?

Phosphorylation at T1079 (LATS1) and T1041 (LATS2) represents a critical activation event in the Hippo signaling pathway. These sites are phosphorylated primarily by upstream kinases STK3/MST2 and STK4/MST1, which occurs in complex with the regulatory protein SAV1 . This phosphorylation event is essential for LATS1/2 kinase activation, allowing them to subsequently phosphorylate and inactivate downstream effectors YAP1 and WWTR1/TAZ . The phosphorylation status at these specific residues serves as a direct molecular readout of LATS1/2 activation state in experimental settings.

How do LATS1 and LATS2 differ functionally despite their structural similarities?

Despite sharing considerable sequence homology and similar activation mechanisms, LATS1 and LATS2 demonstrate distinct biological functions:

These differences underscore the importance of studying both kinases individually despite their overlapping roles in the Hippo pathway .

What experimental controls should be included when validating Phospho-LATS1/LATS2 (T1079/1041) antibody specificity?

Proper validation requires multiple controls:

• Blocking peptide controls: Immunohistochemical staining should be performed with and without the phospho-specific blocking peptide. Complete signal abolishment with the blocking peptide confirms specificity as demonstrated in immunohistochemical staining of human brain tissue .

• Phosphatase treatment: Samples should be treated with lambda phosphatase prior to immunoblotting to confirm the antibody recognizes only the phosphorylated form.

• Genetic validation: Using LATS1/2 knockout cell lines as negative controls, or cells expressing phosphorylation-deficient mutants (T1079A/T1041A) to verify signal specificity.

• Stimulation controls: Compare samples from cells treated with known LATS1/2 activators (e.g., contact inhibition, serum starvation) versus inhibitory conditions .

What are optimized protocols for detecting phosphorylated LATS1/LATS2 via Western blotting?

For optimal detection of phosphorylated LATS1/LATS2 by Western blotting:

• Sample preparation: Rapidly lyse cells in buffer containing phosphatase inhibitors (sodium fluoride, sodium orthovanadate, and phosphatase inhibitor cocktail) to preserve phosphorylation status.

• Protein loading: Load 20-40 μg of total protein per lane. LATS1/2 are relatively large proteins (approximately 120-140 kDa) , requiring adequate gel separation.

• Transfer conditions: Use wet transfer at low voltage (30V) overnight at 4°C for efficient transfer of high molecular weight proteins.

• Blocking: 5% BSA in TBST is preferred over milk, as milk contains phosphatases that may reduce signal.

• Antibody dilution: Use 1:1000 dilution for primary antibody in 5% BSA/TBST and incubate overnight at 4°C .

• Detection: Enhanced chemiluminescence systems with longer exposure times (1-5 minutes) may be necessary for optimal signal detection.

• Stripping and reprobing: When analyzing total LATS1/2 on the same membrane, gentle stripping is recommended to prevent signal loss.

How can immunohistochemistry protocols be optimized for LATS1/LATS2 phosphorylation detection in tissue sections?

For optimal immunohistochemical detection:

• Fixation: Use 10% neutral-buffered formalin for tissue fixation, limiting time to 24 hours to preserve phospho-epitopes.

• Antigen retrieval: Heat-induced epitope retrieval using citrate buffer (pH 6.0) at 95-98°C for 20 minutes provides optimal results for phospho-specific antibodies.

• Blocking: Use 10% normal goat serum to reduce background staining.

• Antibody dilution: The recommended dilution range is 1:50-1:100 for immunohistochemical applications .

• Incubation conditions: Overnight incubation at 4°C yields stronger and more specific signals compared to shorter incubations at room temperature.

• Signal development: DAB (3,3'-diaminobenzidine) substrate is recommended for visualization, with development time of 3-5 minutes.

• Counterstaining: Light hematoxylin counterstaining for 30 seconds provides adequate nuclear contrast without obscuring specific signals.

What approaches are effective for monitoring LATS1/LATS2 phosphorylation dynamics in living cells?

Several techniques can be employed to study real-time phosphorylation dynamics:

• Phospho-specific fluorescent reporters: Genetically encoded FRET-based biosensors containing LATS1/2 phosphorylation motifs allow real-time monitoring of kinase activity in living cells.

• Split luciferase complementation assays: Systems designed to detect LATS1/2 conformational changes upon phosphorylation provide temporal insights into activation dynamics.

• Time-resolved immunofluorescence: Sequential fixation and staining of cells at defined time points following stimulation allows reconstruction of phosphorylation kinetics.

• Proximity ligation assays (PLA): This technique can detect interactions between phosphorylated LATS1/2 and binding partners with high sensitivity and spatial resolution within cells.

Each approach offers different advantages for tracking the temporal and spatial dynamics of LATS1/2 phosphorylation events in response to various stimuli.

How does LATS1 specifically contribute to interferon signaling independent of its role in the Hippo pathway?

Recent research has uncovered a critical role for LATS1, but not LATS2, in type-I interferon (IFN-I) signaling:

• Receptor association: LATS1 constitutively binds with the IFN-I receptor subunit IFNAR2, positioning it for rapid activation upon interferon stimulation .

• Activation mechanism: Upon IFN-I binding, LATS1 undergoes tyrosine phosphorylation by Tyk2 at residues Y200 and Y277, which subsequently promotes activating phosphorylation at S909 and T1079 .

• STAT1 regulation: Activated LATS1 enhances STAT1 phosphorylation specifically at S727 (but not Y701), which is critical for full transcriptional activation of interferon-stimulated genes (ISGs) .

• Antiviral function: LATS1-deficient mice (Lats1+/-) show significantly increased viral loads and mortality when challenged with viruses, demonstrating its biological importance in host defense .

• Pathway specificity: This function is unique to IFN-I signaling, as other cytokines like TNFα and IL-6 do not activate LATS1 phosphorylation .

This mechanism represents a previously unrecognized function of LATS1 distinct from Hippo pathway signaling and highlights the functional divergence between LATS1 and LATS2.

What is the mechanistic basis for LATS2's kinase-independent regulation of the JNK signaling pathway?

LATS2 exhibits significant kinase-independent functions in stress response pathways:

• ASK1 interaction: LATS2 directly binds to Apoptosis Signal-regulating Kinase 1 (ASK1), a critical mediator of stress response, independent of its kinase activity .

• Pathway specificity: LATS2 association with ASK1 selectively enhances JNK activation but not p38 MAPK phosphorylation, suggesting a targeted regulatory mechanism .

• Structural requirements: The interaction and functional enhancement occur independently of LATS2's kinase activity, as kinase-dead mutants maintain the ability to activate ASK1-JNK signaling .

• Cellular outcome: This interaction promotes apoptosis in response to cellular stress, representing a tumor-suppressive mechanism distinct from canonical Hippo pathway signaling .

• Validation approach: Studies using LATS2 knockout cell lines confirmed reduced JNK phosphorylation in response to stress stimuli, validating this non-canonical function .

This kinase-independent function underscores the multifaceted roles of LATS proteins beyond their canonical signaling activities and suggests potential therapeutic approaches targeting specific protein-protein interactions rather than kinase activity.

How does LATS1 regulate autophagy independent of its kinase activity?

LATS1 exhibits unique regulation of autophagy through mechanisms independent of its canonical kinase function:

• Beclin-1 interaction: LATS1, but not LATS2, stabilizes the autophagy core-machinery component Beclin-1 by promoting K27-linked ubiquitination at lysine residues K32 and K263 .

• Functional consequence: This ubiquitination negatively regulates autophagy by promoting formation of inactive Beclin-1 dimers, thereby restricting autophagosome formation .

• Therapeutic relevance: In hepatocellular carcinoma (HCC) cells, LATS1 restricts lethal autophagy induced by sorafenib, the standard treatment for advanced HCC patients, potentially contributing to treatment resistance .

• Experimental validation: LATS1 knockout in HCC cells enhanced sorafenib-induced autophagy and cell death, while re-expression of kinase-dead LATS1 mutants still suppressed autophagy, confirming the kinase-independent nature of this regulation .

This finding highlights a scaffolding role for LATS1 in mediating cross-talk between Hippo signaling and autophagy pathways, representing a potential therapeutic target in cancer treatment strategies.

How can researchers address inconsistencies between observed LATS1/2 phosphorylation and downstream YAP activity?

Discrepancies between LATS1/2 phosphorylation and downstream YAP activity may arise from several factors:

• Alternative YAP regulators: YAP can be regulated by LATS-independent mechanisms, including direct phosphorylation by other kinases or sequestration by proteins such as angiomotin family members .

• Feedback mechanisms: Active YAP can induce expression of negative regulators of the Hippo pathway, creating complex feedback loops that complicate interpretation.

• Subcellular compartmentalization: LATS1/2 activity may be spatially restricted within cells, affecting only a subset of the total YAP pool.

• Post-translational modifications: Additional modifications of YAP (acetylation, methylation, ubiquitination) can override LATS-mediated phosphorylation signals.

• Threshold effects: A certain threshold of LATS1/2 activity may be required for effective YAP regulation, below which correlations may be weak.

Methodological approaches to address these inconsistencies include:

• Comprehensive analysis of multiple YAP phosphorylation sites beyond S127

• Assessment of YAP subcellular localization by fractionation or imaging

• Investigation of LATS-independent YAP regulatory mechanisms

• Use of phosphatase inhibitors to preserve transient phosphorylation events

What factors influence the differential activation of LATS1 versus LATS2 in experimental settings?

Despite structural similarities, LATS1 and LATS2 can be differentially activated:

When designing experiments to study isoform-specific functions:

• Use selective stimuli known to preferentially activate one isoform

• Employ isoform-specific genetic knockdown/knockout approaches

• Consider compensatory mechanisms that may mask phenotypes

• Utilize phospho-specific antibodies that distinguish between the isoforms

Why might researchers observe variability in detecting phosphorylated LATS1/2 across different experimental systems?

Several factors contribute to variability in phospho-LATS1/2 detection:

• Rapid dephosphorylation: Phosphorylated LATS1/2 can be rapidly dephosphorylated by cellular phosphatases, particularly during sample preparation. Ensure samples are processed rapidly with adequate phosphatase inhibitors (sodium fluoride, sodium orthovanadate, phosphatase inhibitor cocktails).

• Expression levels: Endogenous LATS1/2 expression varies significantly across cell types. Tissues with highest expression include heart and skeletal muscle for LATS1, while LATS2 shows a broader distribution .

• Antibody cross-reactivity: Some phospho-specific antibodies may preferentially detect one isoform despite being marketed for both. Validate specificity using isoform-specific knockdown controls.

• Contextual regulation: The kinetics and magnitude of LATS1/2 phosphorylation depend on cellular context. For example, cell density and confluency strongly affect baseline phosphorylation levels .

• Storage conditions: Phospho-epitopes are particularly sensitive to degradation. Store antibodies according to manufacturer recommendations (typically at -20°C in 50% glycerol with 0.02% sodium azide) .

For improved reproducibility:

• Standardize cell culture conditions, particularly cell density

• Include appropriate positive controls (e.g., MST1/2 overexpression)

• Use freshly prepared lysates whenever possible

• Consider enrichment approaches (immunoprecipitation) for low abundance targets

How does LATS1/2 phosphorylation status influence pancreatic β-cell survival and diabetes pathophysiology?

Recent research has revealed critical roles for LATS2 in pancreatic β-cell biology and diabetes:

• Activation in diabetic conditions: LATS2 is hyperactivated under diabetic conditions, contributing to β-cell apoptosis and impaired insulin secretion .

• Protective effect of deficiency: LATS2 deficiency in β-cells and isolated human islets improves β-cell viability, insulin secretion and β-cell mass, ameliorating diabetes development .

• Mechanistic link to mTORC1: LATS2 activates mechanistic target of rapamycin complex 1 (mTORC1), which suppresses protective autophagy in β-cells. Genetic and pharmacological inhibition of mTORC1 counteracts the pro-apoptotic action of activated LATS2 .

• Feedback regulation: LATS2 itself is an autophagy substrate, creating a stress-sensitive multicomponent cellular loop coordinating β-cell compensation and survival .

These findings suggest LATS2 as a potential therapeutic target to improve pancreatic β-cell survival and function in diabetes, representing an application beyond traditional cancer-focused research on the Hippo pathway.

What novel experimental approaches are being developed to target LATS1/2 activity for therapeutic purposes?

Several innovative approaches are being developed to modulate LATS1/2 activity:

• Peptide-based inhibitors: Synthetic peptides mimicking the binding interface between LATS1/2 and scaffolding proteins (e.g., MOB1) can disrupt essential protein-protein interactions required for activation.

• Small molecule modulators: Compounds targeting specific LATS1/2 domains are being developed, including:

  • ATP-competitive inhibitors targeting the kinase domain

  • Allosteric modulators affecting protein conformation

  • Compounds disrupting protein-protein interactions

• Context-dependent targeting: Approaches to modulate LATS1/2 in specific settings:

  • In cancer contexts: inhibitors to enhance YAP activity in senescent cells

  • In diabetes: LATS2 inhibitors to enhance β-cell survival

  • In viral infections: LATS1 activators to enhance interferon responses

• Gene therapy approaches: Development of tissue-specific LATS1/2 modulation using CRISPR/Cas9-based gene editing or RNA interference delivered via targeted nanoparticles.

• Post-translational modification modulators: Compounds targeting specific regulatory modifications, such as inhibitors of phosphatases that dephosphorylate LATS1/2 activation sites.

These diverse approaches reflect the complex and context-dependent functions of LATS1/2 in different biological systems and disease states.

How do non-canonical functions of LATS1/2 influence their role in cancer and other diseases?

Beyond their canonical roles in the Hippo pathway, LATS1/2 exhibit several non-canonical functions with significant disease implications:

• Interferon signaling: LATS1's essential role in interferon-mediated antiviral immunity suggests implications for viral infections and immunotherapies. LATS1-deficient mice show impaired interferon responses and increased susceptibility to viral infection .

• Autophagy regulation: LATS1's kinase-independent regulation of autophagy through Beclin-1 ubiquitination influences cellular responses to stress and therapeutic agents. This function specifically contributes to sorafenib resistance in hepatocellular carcinoma .

• Stress response pathways: LATS2's interaction with ASK1 enhances JNK signaling independent of its kinase activity, promoting apoptosis in response to cellular stress. This represents a tumor-suppressive mechanism distinct from canonical Hippo signaling .

• Metabolic regulation: LATS2 activation in pancreatic β-cells contributes to cell death and impaired function in diabetes, suggesting a previously unrecognized role in metabolic disease .

• Genome stability: Both LATS1 and LATS2 contribute to genome integrity through mechanisms involving p53 regulation and mitotic fidelity, with LATS1 affecting G2/M transitions and LATS2 regulating G1/S progression .

These non-canonical functions highlight the need for context-specific approaches when targeting LATS1/2 in different disease settings, as global inhibition or activation may lead to unexpected effects across multiple biological systems.